UPDATE: FDA Has Recommended Neovasc Consider Potential Alternate Approaches Such As The Humanitarian Device Exemption Pathway For Class IV Refractory Angina Patients And/Or Alternate Clinical Trial Designs For A Broader Refractory Angina